{"data":[{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Management, L.L.C.","reportingCik":null,"personType":"IA,OO","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"HC,IN","sharesOwned":16270187,"percentOfClass":9.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-352271","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":10147867,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-352271","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":10147867,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-352271","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":10147867,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000886982-26-000510","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"TANGO THERAPEUTICS, INC.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"THE GOLDMAN SACHS GROUP, INC.","reportingCik":null,"personType":"HC,CO","sharesOwned":9742402.8,"percentOfClass":6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000886982-26-000510","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"TANGO THERAPEUTICS, INC.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"GOLDMAN SACHS & CO. LLC","reportingCik":null,"personType":"BD,OO,IA","sharesOwned":9742402.8,"percentOfClass":6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-005265","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Woodline Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4000567,"percentOfClass":2.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Nextech Crossover I GP S.a. r.l.","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Nextech Crossover I SCSp","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Ian Charoub","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Costas Constantinides","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Rocco Sgobbo","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000425","formType":"SCHEDULE 13G/A","amendmentNo":5,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-06-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-004954","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":5600000,"percentOfClass":3.44,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-004954","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":5600000,"percentOfClass":3.44,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-004954","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":5600000,"percentOfClass":3.44,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001493215-26-000120","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Roderick Wong","reportingCik":null,"personType":"HC,IN","sharesOwned":13300620,"percentOfClass":9.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001493215-26-000120","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"RTW Investments, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":13300620,"percentOfClass":9.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-226866","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":11597737,"percentOfClass":8.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-226866","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":11597737,"percentOfClass":8.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-226866","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":11597737,"percentOfClass":8.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-003243","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Woodline Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":8000013,"percentOfClass":5.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Costas Constantinides","reportingCik":null,"personType":"IN","sharesOwned":7266081,"percentOfClass":5.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Nextech Crossover I GP S.a. r.l.","reportingCik":null,"personType":"OO","sharesOwned":7266081,"percentOfClass":5.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Nextech Crossover I SCSp","reportingCik":null,"personType":"PN","sharesOwned":7266081,"percentOfClass":5.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Ian Charoub","reportingCik":null,"personType":"IN","sharesOwned":7266081,"percentOfClass":5.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001916761-26-000005","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-03-31","reportingPerson":"Rocco Sgobbo","reportingCik":null,"personType":"IN","sharesOwned":7266081,"percentOfClass":5.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-002933","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":12809485,"percentOfClass":8.98,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-002933","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":12809485,"percentOfClass":8.98,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000919574-26-002933","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":12809485,"percentOfClass":8.98,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":11257203,"percentOfClass":7.8,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":10964477,"percentOfClass":7.6,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5008902,"percentOfClass":3.5,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":5008902,"percentOfClass":3.5,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2488434,"percentOfClass":1.7,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1470591,"percentOfClass":1,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1055717,"percentOfClass":0.7,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":260503,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":290563,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":260503,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":292726,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":292726,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":226033,"percentOfClass":0.2,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000221","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2026-03-31","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":163734,"percentOfClass":0.1,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000315066-26-001324","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"TANGO THERAPEUTICS INC","ticker":"TNGX","cusip":"87583X109","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":9905919,"percentOfClass":6.9,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000315066-26-001324","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"TANGO THERAPEUTICS INC","ticker":"TNGX","cusip":"87583X109","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":9905919,"percentOfClass":6.9,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":5657105,"percentOfClass":4,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":4964650,"percentOfClass":3.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4964650,"percentOfClass":3.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4964650,"percentOfClass":3.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":4964650,"percentOfClass":3.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":692455,"percentOfClass":0.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":692455,"percentOfClass":0.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000027","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":692455,"percentOfClass":0.5,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000102909-26-002402","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics Inc","ticker":"TNGX","cusip":"87583X109","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-054743","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":13521839,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-054743","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"TCG Crossover GP II, L.P.","reportingCik":null,"personType":"OO","sharesOwned":13521839,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-054743","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":13521839,"percentOfClass":9.99,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-26-001066","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Woodline Partners LP","reportingCik":null,"personType":"IA,PN","sharesOwned":10072225,"percentOfClass":7.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000935836-26-000119","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"EcoR1 Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000935836-26-000119","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Oleg Nodelman","reportingCik":null,"personType":"HC,IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000935836-26-000119","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"EcoR1 Capital Fund Qualified, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":8165374,"percentOfClass":6.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":7068444,"percentOfClass":5.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":7068444,"percentOfClass":5.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":7068444,"percentOfClass":5.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":7068444,"percentOfClass":5.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":1096930,"percentOfClass":0.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":1096930,"percentOfClass":0.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-26-000012","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":1096930,"percentOfClass":0.8,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-26-000912","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":10607924,"percentOfClass":7.88,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-26-000912","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":10607924,"percentOfClass":7.88,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-26-000912","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":10607924,"percentOfClass":7.88,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-044719","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-06","reportingPerson":"Third Rock Ventures IV, L.P.","reportingCik":"0001688327","personType":"PN","sharesOwned":6374574,"percentOfClass":4.74,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-044719","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-06","reportingPerson":"Third Rock Ventures GP IV, L.P.","reportingCik":"0001688326","personType":"PN","sharesOwned":6374574,"percentOfClass":4.74,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-26-044719","formType":"SCHEDULE 13D/A","amendmentNo":4,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2026-02-06","reportingPerson":"TRV GP IV, LLC","reportingCik":"0001688325","personType":"OO","sharesOwned":6374574,"percentOfClass":4.74,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Husen, Avner A.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":13461215,"percentOfClass":9.99,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":12905118,"percentOfClass":9.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5280943,"percentOfClass":3.9,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2922242,"percentOfClass":2.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2199950,"percentOfClass":1.6,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":710502,"percentOfClass":0.5,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":496032,"percentOfClass":0.4,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":556097,"percentOfClass":0.4,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":605612,"percentOfClass":0.4,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":556097,"percentOfClass":0.4,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":605612,"percentOfClass":0.4,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":359837,"percentOfClass":0.3,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners Master, L.P.","reportingCik":null,"personType":"PN","sharesOwned":330000,"percentOfClass":0.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Farallon Healthcare Partners (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":330000,"percentOfClass":0.2,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Fried, Richard B","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Patel, Rajiv A.","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-26-000056","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Seybold, William","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000102909-26-000267","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics Inc","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":6750977,"percentOfClass":5.01,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002012383-26-000726","formType":"SCHEDULE 13G","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":8477165,"percentOfClass":6.3,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-291391","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-19","reportingPerson":"Third Rock Ventures IV, L.P.","reportingCik":"0001688327","personType":"PN","sharesOwned":7874574,"percentOfClass":5.85,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-291391","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-19","reportingPerson":"Third Rock Ventures GP IV, L.P.","reportingCik":"0001688326","personType":"PN","sharesOwned":7874574,"percentOfClass":5.85,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-291391","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-19","reportingPerson":"TRV GP IV, LLC","reportingCik":"0001688325","personType":"OO","sharesOwned":7874574,"percentOfClass":5.85,"filedAt":"2025-11-21","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-282980","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-12","reportingPerson":"Third Rock Ventures IV, L.P.","reportingCik":"0001688327","personType":"PN","sharesOwned":9374574,"percentOfClass":6.97,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-282980","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-12","reportingPerson":"Third Rock Ventures GP IV, L.P.","reportingCik":"0001688326","personType":"PN","sharesOwned":9374574,"percentOfClass":6.97,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-282980","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-12","reportingPerson":"TRV GP IV, LLC","reportingCik":"0001688325","personType":"OO","sharesOwned":9374574,"percentOfClass":6.97,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-283070","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":8536196,"percentOfClass":6.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-283070","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":8536196,"percentOfClass":6.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0001193125-25-283070","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":8536196,"percentOfClass":6.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-25-004875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":2511000,"percentOfClass":2.26,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-25-004875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":2511000,"percentOfClass":2.26,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000902664-25-004875","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":2511000,"percentOfClass":2.26,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Wehrly, Mark C.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Giauque, Nicolas","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Kim, David T.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Linn, Michael G.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Luo Patrick (Cheng)","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Patel, Rajiv A.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Roberts, Jr., Thomas G.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Saito Edric C.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Seybold, William","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Short Daniel S.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Spokes, Andrew J. M.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Warren, John R.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Dapice Joshua J.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Dreyfuss, Philip D.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Dunn Hannah E.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Fried, Richard B","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Gehani, Varun N.","reportingCik":null,"personType":"IN","sharesOwned":10757000,"percentOfClass":9.7,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Partners, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":10331579,"percentOfClass":9.3,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital Offshore Investors II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4421621,"percentOfClass":4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital Institutional Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2301057,"percentOfClass":2.1,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital Partners, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1792415,"percentOfClass":1.6,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Four Crossings Institutional Partners V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":505935,"percentOfClass":0.5,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Institutional (GP) V, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":505935,"percentOfClass":0.5,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital Institutional Partners II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":589896,"percentOfClass":0.5,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital Institutional Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":417567,"percentOfClass":0.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital F5 Master I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":425421,"percentOfClass":0.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon F5 (GP), L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":425421,"percentOfClass":0.4,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0000908834-25-000328","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common stock, par value $0.001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Farallon Capital (AM) Investors, L.P.","reportingCik":null,"personType":"PN","sharesOwned":303088,"percentOfClass":0.3,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Raymond Debbane","reportingCik":null,"personType":"IN","sharesOwned":5883188,"percentOfClass":5.3,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Invus Public Equities Advisors, LLC","reportingCik":null,"personType":"OO","sharesOwned":5082716,"percentOfClass":4.6,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Invus Global Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":5082716,"percentOfClass":4.6,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Siren, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":5082716,"percentOfClass":4.6,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Invus Public Equities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5082716,"percentOfClass":4.6,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Avicenna Life Sci Master GP LLC","reportingCik":null,"personType":"OO","sharesOwned":800472,"percentOfClass":0.7,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Ulys, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":800472,"percentOfClass":0.7,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"},{"accessionNo":"0002005369-25-000050","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001819133","issuerName":"Tango Therapeutics, Inc.","ticker":"TNGX","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-19","reportingPerson":"Avicenna Life Sci Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":800472,"percentOfClass":0.7,"filedAt":"2025-09-22","canonicalUrl":"https://xoomar.com/markets/stocks/tngx"}],"updatedAt":"2026-11-04T08:05:25.594Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/tngx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}